GlassScriptPhysician profile
Sujay Y Bangarulingam
NPI 1710977640
$3,075.71
in general payments reported to CMS, 2019-2025
23 companies · $68.51 in 2025
The $68.51 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,003 · 2020: $197 · 2021: $14.48 · 2022: $39.42 · 2023: $839 · 2024: $914 · 2025: $68.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,821.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $777.23 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $435.39 | 2019-2024 | Fasenra, Airsupra, Breztri |
| Electromed, INC. | $316.42 | 2019-2024 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.05 | 2019-2024 | Ofev, Spiriva Respimat, Combivent Respimat |
| Philips North America LLC | $273.49 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Jazz Pharmaceuticals INC. | $193.84 | 2019-2024 | Xywav |
| Mylan Specialty L.P. | $137.96 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $117.30 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $82.42 | 2019-2020 | |
| Amgen INC. | $79.16 | 2023-2024 | Tezspire |
| Insmed, INC. | $64.05 | 2019-2025 | Arikayce |
| Genentech USA, INC. | $54.53 | 2019 | |
| Merck Sharp & Dohme LLC | $37.78 | 2019-2020 | |
| Pfizer INC. | $37.03 | 2019-2020 | |
| Advanced Respiratory, INC | $30.10 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $25.76 | 2023 | Inogen At Home Stationary Concentrator |
| Grifols USA, LLC | $24.12 | 2019 | |
| Circassia INC. | $19.96 | 2019 | |
| Verona Pharma, INC. | $16.47 | 2025 | Ohtuvayre |
| Breathe Technologies, INC. | $15.15 | 2019 | |
| Pulmonx Corporation | $14.97 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $14.48 | 2021 | |
| Allergan, INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujay Bangarulingam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.